Benitec has industrial rights for use in human beings and related applications while CSIRO provides exclusive rights for all other applications. CSIRO has continuing to develop and great tune RNAi technology in more than 10 years of research, resulting in a further nine patent families, and establishing CSIRO as an integral player in this region of research. This was confirmed by the recent grant folks Patent No. 6933146 to its ‘Hellsgate’ group of RNAi gene silencing vectors.But suppressing the disease fighting capability makes the individual more susceptible to a virus called cytomegalovirus . Gagermeier and co-workers reviewed records of 51 Loyola lung transplant individuals. Twenty-one sufferers had CMV disease. Ten of these infected individuals responded well to ganciclovir, indicating the virus was eliminated and symptoms improved within 2 weeks. Of the rest of the 11 patients, 6 individuals with sufficient degrees of ganciclovir experienced a delayed but appropriate response to the drug.